

Strep A Vaccine Global Consortium

<https://savac.ivi.int/>

Introduction

- **Group A Streptococcus (Strep A)**
 - A wide spectrum of clinical manifestations – pharyngitis, skin infections, acute rheumatic fever (ARF), and rheumatic heart disease (RHD), etc.
 - Currently no vaccine available against Strep A infections
 - Lack of standardized surveillance programs and economic evaluations
 - Available studies being disproportionately lower in low-income countries than in high-income countries
- **Traditional investment case**
 - Literature review on existing cost-effectiveness analysis (CEA)
 - Estimating the economic burden of Strep A infections
 - Carrying out the cost-effectiveness analysis for a hypothetical Strep A vaccine at the global-level

Methods – Economic burden estimation 1

- **Initial literature search by the TKI team to identify any costs associated with Strep A**
- **Existing costs reported in various formats – manually reviewed and categorized them into:**
 - Direct medical costs (DMC)
 - Direct non-medical costs (DNMC)
 - Indirect costs (IC)
- **Insufficient number of existing studies**
 - By income group (as classified by the World Bank): significantly lower number of studies available in non-high-income countries
 - By disease manifestation: disproportionately low number or absence of economic burden data for multiple disease manifestations
- **Disease outcomes for economic burden estimation**
 - Pharyngitis, ARF, RHD, severe RHD, invasive infections, impetigo, and cellulitis

Methods – Economic burden estimation 2

- **Creating adjustment factors to overcome related data insufficiency**
 - WHO-CHOICE unit cost database
 - Patient type (inpatient, outpatient), Facility type (primary-, secondary-, and tertiary-level)
 - Healthcare big data hub system
 - Frequency of visits, duration of bed-days, number of inpatients / outpatients
 - 10-year period to account for variability
 - The number of outpatient visits / inpatient bed-days per episode
 - GDP per capita
- **Productivity loss due to death**
 - Premature death from RHD and invasive infections
 - The weighted average age of death based on IHME
 - RHD, Invasive infections (pneumococcus and meningococcal meningitis)
 - Multiplying productivity years lost by minimum wage (discounted at the rate of 3%)
- **Sensitivity analysis**
 - A large degree of uncertainty on input parameters
 - Probabilistic multivariate sensitivity analysis
 - Monte Carlo simulation – estimate 95% confidence intervals

Methods – Cost-effectiveness analysis 1

- **A static cohort model and 6 vaccination scenarios set up by the TKI team**
 - Pharyngitis, RHD, invasive infections, impetigo, and cellulitis

Scenario	Assumption
1	Vaccine adoption year (country-specific), coverage rate (country-specific Hib3), full efficacy for 10 years
2	Vaccine adoption year (country-specific), coverage rate (country-specific Hib3), linear waning over 20 years
3	Vaccine adoption year (2022), coverage rate (50%), full efficacy for 10 years
4	Vaccine adoption year (2022), coverage rate (50%), linear waning over 20 years
5	Vaccine adoption year (country-specific), coverage rate (50%), full efficacy for 10 years
6	Vaccine adoption year (country-specific), coverage rate (50%), linear waning over 20 years

- Initial vaccination coverage rate: 10% of the peak coverage rates
- Annual uptake rate of 10% since the year of vaccine introduction

Methods – Cost-effectiveness analysis 2


- **WHO preferred product characteristics (PPC) for a Strep A vaccine**
 - Pharyngitis (80%), RHD (50%), invasive infections (70%), impetigo (80%), cellulitis (70%)

Item	Assumption
Geographical presentation	World Bank income groups (HIC, UMIC, LMIC, LIC)
Vaccine doses	3 doses
Vaccination strategies	Routine at birth; routine at 5 years of age
Cost per fully vaccinated person	\$0 - \$300
Discounting	3% discounting for costs and health outcomes (default); 0% discounting for health outcomes (sensitivity analysis)
Wastage factor during vaccination campaigns	10% (default); 5% and 20% (sensitivity analysis)
Economic burden	Point estimates (default); 95% confidence intervals (sensitivity analysis); societal perspective
Cost-effectiveness threshold	1 x GDP per capita (default); health opportunity costs (conservative)

- **Sensitivity analyses – univariate, as well as multivariate sensitivity analyses**


Results – Economic burden per episode by income group

- Overall, economic burden being higher in HIC than in LIC / for more severe illnesses than for mild infections
- \$22 - \$392 for pharyngitis, \$231 - \$6,332 for ARF, \$449 - \$11,717 for RHD, \$949 - \$39,560 for severe RHD, \$662 - \$34,330 for invasive infections, \$25 - \$2,903 for impetigo, and \$47 - \$2,725 for cellulitis




Results – Productivity loss due to premature death

- Productivity years lost being the lowest in HIC
- Cost due to early death being the greatest in HIC and the lowest in LIC
- Higher income level in the higher-income groups than lower-income groups



Results – Incremental cost-effectiveness ratios (ICERs)

- 5-yo routine vaccination for pharyngitis and RHD
- Infant routine vaccination for invasive infections
- Marginal differences between the two vaccination strategies for skin infections




Incremental cost-effectiveness ratios by income group under scenario 1.

Interventions are considered to be cost-effective if the total cost per fully vaccinated person is located on the left side of varying threshold costs per DALY averted.

Results – Maximum cost per fully vaccinated person

- At the threshold of 1 x GDP per capita
- Pharyngitis (\$8-\$308), RHD (\$6 - \$216), Invasive infections (\$0.2 - \$56), Impetigo (\$1 - \$153), Cellulitis (\$0.1 - \$28), All (\$37 - \$489)



Threshold cost per fully vaccinated person to be cost-effective by income group under scenario 1.

Lower bounds are for the least favorable scenario: 20% wastage rate, lower bound of economic burden, and 3% discounting of health outcomes. Upper bounds are based on the most favorable scenario: 5% wastage rate, upper bound of economic burden, and 0% discounting of health outcomes. Scales on the Y-axes vary.

Findings, limitations, and future research needs

- **Substantial economic burden for Strep A infections**
- **Cost-effective if a threshold cost per fully vaccinated person is properly set**
- **Sensitive to vaccine characteristics**
 - Efficacy, waning, duration of protection, etc.
 - Absence of Strep A vaccines – WHO preferred product characteristics
 - Updates required as clinical trials for potential vaccine candidates advance
- **Scarcity of existing studies on both economic and disease burden for multiple disease outcomes caused by Strep A**
- **Future research needs**
 - Increase a number of primary data points such as surveillance programs, and field-based economic burden studies
 - Lack of evidence in LMICs and LICs

ACKNOWLEDGEMENTS

- **IVI**
 - Jerome Kim, Jean-Louis Excler, Vittal Mogasale, Sol Kim, Somyoung Cho, Chole Hong, Jimin Son
- **FVVA Working group**
 - David Bloom, Daniel Cadarette, Jeffrey Cannon, Fiona Giannini, Kaja Abbas, et al.
- **SAVAC Executive Committee**
- **FVVA Technical Advisory Committee**
- **Wellcome Trust**



Thank you!